Series E · Biotech
Enveda raises $311m Series E at $2bn valuation
Catalio Capital Management led the financing as Enveda advances more nature-derived drug candidates into clinical trials.
Adding clinical programmes from the discovery platform
Catalio Capital Management led Enveda’s $311 million Series E, with ICONIQ and other investors participating. The round values the company at $2 billion.
Enveda will use the financing to bring more drug candidates derived from plants and microbes into clinical trials. Its current clinical work includes skin-condition treatments and programmes intended to help preserve weight loss after patients stop GLP-1 medicines.
Use of funds
Advance nature-derived drug candidates into clinical trials
Funding history
Series E · This round$311M